Potential biological functions and future perspectives of sialylated milk oligosaccharides.
Thuy Le Lam NguyenDung Van NguyenKyung-Sun HeoPublished in: Archives of pharmacal research (2024)
Sialyllactoses (SLs) primarily include sialylated human milk oligosaccharides (HMOs) and bovine milk oligosaccharides (BMOs). First, the safety assessment of 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL) revealed low toxicity in various animal models and human participants. SLs constitute a unique milk component, highlighting the essential nutrients and bioactive components crucial for infant development, along with numerous associated health benefits for various diseases. This review explores the safety, biosynthesis, and potential biological effects of SLs, with a specific focus on their influence across various physiological systems, including the gastrointestinal system, immune disorders, rare genetic disorders (such as GNE myopathy), cancers, neurological disorders, cardiovascular diseases, diverse cancers, and viral infections, thus indicating their therapeutic potential.
Keyphrases
- human milk
- cardiovascular disease
- endothelial cells
- healthcare
- low birth weight
- public health
- human health
- sars cov
- mental health
- oxidative stress
- gene expression
- metabolic syndrome
- heavy metals
- risk assessment
- preterm infants
- copy number
- induced pluripotent stem cells
- health information
- cardiovascular events
- dna methylation
- health promotion
- brain injury